Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;25(2):e396-e397.
doi: 10.1634/theoncologist.2019-0515. Epub 2019 Nov 6.

In Reply

Blake Warner  1 , Alan Baer  1   2
Affiliations
Comment

In Reply

Blake Warner et al. Oncologist. 2020 Feb.

Abstract

This letter to the editor is in response to the letter from Brugu's and colleagues regarding the Warner et al. study of sicca syndrome induced by immune checkpoint inhibitor therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Some patients with immune checkpoint‐induced sicca experienced objective improvements in saliva flow (4/9) using a graded approach as described in Warner et al. 2. However, even with modest objective improvement in saliva flow, all patients remained CTCAE grade 3 using objective criteria for “dry mouth.”
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Ortiz Brugués A, Sibaud V, Herbault‐Barrés B et al. Sicca syndrome induced by immune checkpoint inhibitor therapy: Optimal management still pending. The Oncologist 2020;25:e391–e395. - PMC - PubMed
    1. Warner BM, Baer AN, Lipson EJ et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. The Oncologist 2019;24:1259–1269. - PMC - PubMed
    1. Burbelo PD, Ferré EMN, Chaturvedi A et al. Profiling autoantibodies against salivary proteins in sicca conditions. J Dent Res 2019. Jul;98:772–778. - PMC - PubMed
    1. Arbour KC, Mezquita L, Long N et al. Impact of baseline steroids on efficacy of programmed cell death‐1 and programmed death‐ligand 1 blockade in patients with non‐small‐cell lung cancer. J Clin Oncol 2018;36:2872–2878. - PubMed
    1. Ricciuti B, Dahlberg SE, Adeni A et al. Immune checkpoint inhibitor outcomes for patients with non‐small‐cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol 2019;37:1927–1934. - PubMed